Analysts await Capricor Therapeutics, Inc. (NASDAQ:CAPR) to report earnings on Mar, 17 for the fiscal quarter ending Dec 2015.

They expect $-0.19 EPS, down 15.79% or $0.03 from last year’s $-0.16 per share.

At the moment 1 analyst is watching Capricor Therapeutics, Inc. (NASDAQ:CAPR), 0 rate it “Buy”, 1 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 1 analyst has a mean sales target of 1.10 million. For the quarter ending Jun-16, 1 analyst has a mean sales target of 1.10 million whilst for the year ending Dec-16, 1 analyst has a mean target of 2.20 million.

In terms of earnings per share, 1 analyst has a -0.20 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 1 analyst has a -0.20 EPS mean target and for the quarter ending Jun-16 there are 1 estimate of -0.91 EPS.

The biggest institutional shareholders in Capricor Therapeutics, Inc. include Cedars Sinai Medical Center which owns 2 million shares in the company valued at $8.16 million. NANCELOU, Inc is the second biggest holder with 1 million shares currently valued at 6.05 million whilst Coniston Corp has 638 K million shares valued at 3.71 million.

Total shares held by institutions as of the most recent company filings are 274,155 with a reported 0 bought and 64,786 sold. These holdings make up 1.69% of the company’s outstanding shares.

Currently insiders hold 4,763,168 shares in the business which makes up 29.30% of shares. The biggest holder currently is Peter Morgan Kash who owns 1,596,208 shares (9.82% of those outstanding), whilst David M. Tanen holds 1,520,705 (9.36% of shares outstanding) and Mr. Joshua A. Kazam holds 1,328,228 (8.17% of shares outstanding).

The stock increased 5.93% or $0.14 during the last trading session, hitting $2.61. Capricor Therapeutics, Inc. (NASDAQ:CAPR) has fallen 59.77% over the past 6 months and is downtrending.